Murat Karabacak

Murat Karabacak

Auto-generated profile, based on publicly available information

Murat Karabacak

Department of Rheumatology, Marmara University Medical Faculty, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
UGUmmugulsum Gazel
Ummugulsum Gazel
DKDerya Kocakaya
Derya Kocakaya
ITİrEm Hi̇cRet Topçu
İrEm Hi̇cRet Topçu
HKHakan Ömer Karataş
Hakan Ömer Karataş
MKMurat Karabacak
Murat Karabacak
RDRafi Haner Di̇rEskeneli̇
Rafi Haner Di̇rEskeneli̇
Tumor necrosis factor-alfa (TNF-?) antagonists are extensively utilized in the treatment of inflammatory rheumatic diseases and also shown to be effective in Behcet?s disease (BD) patients with major organ involvement. In this study, we aimed to re-evaluate the incidence of tuberculosis (TB) infection after anti-TNF? treatments and to reveal the risk of TB in BD. Data of patients who received anti-TNF? treatment between 2005 and 2018 were assessed retrospectively. Demographic features, TNF-? antagonist type/treatment time, Tuberculosis skin test (TST) and QuantiFERON results, isoniazid prophylaxis status, and concomitant corticosteroid (CS) treatments were collected. A total of 1277 (male/female = 597/680; median age = 49 years) patients were treated with TNF-? antagonist for a median of 33 months (Q1:12, Q3:62). Thirteen (1%) patients developed TB during the follow-up period. Within 13 TB-positive patients, 7 of them had pulmonary, and 7 had extrapulmonary TB. Although, the median time of (month) TNF-? antagonist treatment was higher in TB-positive patients than negative ones, the difference was not statistically significant (48 and 33 months, respectively, p=0.47). Similarly, TB-positive patients were treated with CSs more than TB-negative patients (80% vs. 60%). Time from the initiation of TNF-? antagonist treatment to the diagnosis of TB had a median of 40 months (Q1-Q3: 22-56). There was a statistically significant increase of TB development in BD patients than non-BD patients after TNF-? antagonists (7.5% vs. 0.8%, respectively, p=0.007). When we combined our patients with the other series from Turkey, among 12928 patients who received TNF-? antagonists, TB was positive in 12 (3,9%) of 305 BD patients compared to 112 (0.9%) of 12623 non-BD patients (p<0.00001). Our results suggest a higher frequency of TB infections in BD patients with TNF-? antagonists. As biologic agents are increasingly used for major organ involvement in current practice for BD, screening mechanisms should be carefully implemented.

13 November 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
TBTugce Bozkurt
Tugce Bozkurt
MYMehmet Yildiz
Mehmet Yildiz
RDRabia Deniz
Rabia Deniz
AYAyten Yazici
Ayten Yazici
MKMurat Karabacak
Murat Karabacak
FAFatma Alibaz-Oner
Fatma Alibaz-Oner
Although Behçet's disease (BD) typically manifests in the second or third decade of life, initial symptoms may appear at a younger age. It may also take a longer time for the full disease phenotype to develop after the first symptom onset in pediatric patients. In this study we aimed to assess the clinical course of pediatric-onset BD in adulthood period. The files of 112 patients diagnosed with BD before the age of 18, selected from five tertiary clinics, were retrospectively examined. Patients with a follow-up of less than six months were excluded. The study comprised 93 patients with pediatric-onset BD, of whom 64.5% (n = 60) were male. The median age of diagnosis was 15 years (13–17). Major organ involvement was present in 49 (52.5%) patients. The most commonly affected organ was the eye (29%). Sixty-eight (73.1%) patients had follow-up data in adulthood. Fourty patients had only mucocutaneous manifestations in the pediatric period. During follow-up in adulthood, 15 (53.3% were male) had new major organ involvement with a mean of 10.1 (SD: 7.9) years after diagnosis. Twenty-eight patients (41.1%) experienced major organ involvement during the pediatric period. In adulthood follow-up, 12 (42.8%) developed new major organ involvement and/or relapse of the same organ. Eighteen (26.5%) of 68 pediatric-onset BD patients had new major organ involvement, and 9 (13.2%) had a relapse during adulthood follow-up. Our results showed that nearly one-third of pediatric BD patients have a new major organ involvement or a relapse in adulthood. Regular follow-up of pediatric BD patients in adulthood is essential to prevent long-term damage in this disease subset.

24 November 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
IEIlkay Ergenc
Ilkay Ergenc
HKHaluk Tarık Kani
Haluk Tarık Kani
MKMurat Karabacak
Murat Karabacak
EÖElif Cömert Özer
Elif Cömert Özer
SMShahin Mehdiyev
Shahin Mehdiyev
ÖAÖzlen Atuğ
Özlen Atuğ
Background: The risk of hepatitis B reactivation in hepatitis B surface antigen-negative phase of hepatitis B virus-infected patients exposed to biologic agents is not clear. We aimed to investigate the reactivation rate in hepatitis B surface antigen-negative phase of hepatitis B virus-infected patients after biologic therapy. Methods: Patients followed at gastroenterology, rheumatology, and dermatology clinics with a diagnosis of immune-mediated inflammatory diseases were screened. Immune-mediated inflammatory diseases patients exposed to biologic agents with a negative hepatitis B surface antigen and positive hepatitis B core immunoglobulin G antibody were included in the study. Results: We screened 8266 immune-mediated inflammatory disease patients, and 2484 patients were identified as exposed to biologic agents. Two hundred twenty-one patients were included in the study. The mean age was 54.08 ± 11.69 years, and 115 (52.0%) patients were female. The median number of different biologic subtype use was 1 (range: 1-6). The mean biologic agent exposure time was 55 (range: 2-179) months. One hundred and fifty-two (68.8%) patients used a concomitant immunomodulatory agent, and 84 (38.0%) patients were exposed to corticosteroids during biologic use. No hepatitis B reactivation with a reverse seroconversion of hepatitis B surface antigen positivity was seen. Antiviral prophylaxis for hepatitis B was applied to 48 (21.7%) patients. Hepatitis B virus-DNA was screened in 56 (25.3%) patients prior to the biologic exposure. Two patients without antiviral prophylaxis had hepatitis B virus-DNA reactivation with a negative hepatitis B surface antigen during exposure to the biologic agent. Conclusion: We found 2 reactivations and no hepatitis B surface antigen seroconversion in our cohort. Antiviral prophylaxis for patients exposed to biologic agents may need to be discussed in more detail. Cite this article as: Ergenç İ, Kani HT, Karabacak M, et al. Biologic therapy carries a very low risk of reactivation in hepatitis B surface antigen-negative phase of hepatitis B. Turk J Gastroenterol. 2023;34(2):156-160.

18 February 2025 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
TITuba Yuce Inel
Tuba Yuce Inel
MKMurat Karabacak
Murat Karabacak
FOFatos Onen
Fatos Onen
MBMerih Birlik
Merih Birlik

14 March 2023 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
IEIlkay Ergenc
Ilkay Ergenc
HKHaluk Tarık Kani
Haluk Tarık Kani
MKMurat Karabacak
Murat Karabacak
EÖElif Cömert Özer
Elif Cömert Özer
SMShahin Mehdiyev
Shahin Mehdiyev
ÖAÖzlen Atuğ
Özlen Atuğ
Cite this article as: Ergenç İ, Kani HT, Karabacak M, et al. RE: risk of HBV reactivation in HBsAg negative and anti-HBc IgG positive patients receiving biologic therapy. Turk J Gastroenterol. 2023;34(3):310.

16 January 2026 in Archives of Rheumatology
Verified
Journal Article
Open access
PDF file
MKMeltem Karacaatlı
Meltem Karacaatlı
KAKerem Abacar
Kerem Abacar
MKMurat Karabacak
Murat Karabacak
İYİlker Yağcı
İlker Yağcı
FAFatma Alibaz-Oner
Fatma Alibaz-Oner
OKOzge Kenis
Ozge Kenis
Background/Aims: This study aimed to evaluate the effectiveness of therapeutic exercises in improving muscle strength, functional status, and quality of life in patients receiving high-dose glucocorticoid therapy, which is known to cause muscle weakness and atrophy. Materials and Methods: This randomized, controlled, single-center study included 40 participants aged 18-65 years who received high-dose glucocorticoids due to chronic rheumatologic conditions, and the patients were divided into 2 groups: an exercise group and a control group. The exercise group performed lower-extremity resistance exercises for 3 months. The exercise program consisted of squats, seated leg extensions, seated leg curls, hip abductions, and seated calf raises performed 5 days per week. Functional assessments included the 6-minute walk test, the Five Times Sit To Stand Test, and the Timed Up and Go Test. Muscle strength was measured using a dynamometer, quality of life was assessed with the Short Form Health Survey questionnaire, and the cross-sectional area (CSA) of the rectus femoris muscle was evaluated via B-mode ultrasound. Patients were assessed at baseline and after 3 months of treatment. Results: Twenty patients were included in each group, with no significant differences in baseline characteristics. Compared with the control group, a significant increase was observed in knee extension strength (P = .00 for right and left knees) and quality of life in terms of physical function in the exercise group. However, no significant differences were found in the 6-minute walk test, the Five Times Sit To Stand Test, the Timed Up and Go Test, or the rectus femoris muscle CSA. Conclusion: In patients with rheumatologic diseases treated with highdose glucocorticoids, resistance exercise therapy can increase knee extension strength and quality of life in terms of physical function. Cite this article as: Karacaatlı M, Abacar K, Karabacak M, et al. The impact of resistance exercise program on muscle strength, functional performance, and quality of life in patients with rheumatologic disease receiving high-dose glucocorticoids treatment: A randomized trial. ArchRheumatol. 2026;41(1):40-46.